New cocktail aims to tackle tough lymphoma
NCT ID NCT07638787
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This early-stage trial tests whether adding sonrotoclax to standard Pola-R-CHP chemotherapy can improve outcomes for people with untreated large B-cell lymphoma that has high BCL2 expression or double-hit features. The study has two parts: first, finding a safe dose of sonrotoclax, then checking how well the combination works in 40 patients aged 18-75.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sonrotoclax combined with polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP)
- What this could lead to
- If successful, this combination could offer a more effective first-line treatment for aggressive large B-cell lymphoma with high BCL2 expression or double-hit genetics.
- What could go wrong
- This is an early Phase 1/2 trial with only 40 participants, so safety and effectiveness are not yet proven. The added drug may increase side effects without improving outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DOUBLE-HIT LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ruijin Hospital, Shanghai JiaoTong University School of Medicine
Shanghai, Shanghai Municipality, 200025, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can a single shot build a cancer army inside the body?
- New combo therapy aims to boost remission in Hard-to-Treat lymphoma
- Engineered immune cells get a boost: new combo therapy targets Hard-to-Treat blood cancers
- New combo aims to boost lymphoma control in older patients
- New hope for lymphoma patients when CAR-T fails